Patents by Inventor Karl Richard Gibson
Karl Richard Gibson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220023281Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: ApplicationFiled: November 15, 2019Publication date: January 27, 2022Inventors: Gareth RICHARDS, Timothy M. SKERRY, Joseph P.A. HARRITY, Jean-Olivier ZIRIMWABAGABO, Matthew J. TOZER, Karl Richard GIBSON, Roderick Alan PORTER, Paul Alan GLOSSOP
-
Patent number: 11136325Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.Type: GrantFiled: July 12, 2018Date of Patent: October 5, 2021Assignee: GALAPAGOS NVInventors: David Amantini, Milan Mesic, Gordon Saxty, Tanja Poljak, Ines Vujasinovic, Dinko Ziher, David Witty, Karl Richard Gibson
-
Publication number: 20210113534Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein R1, R2, R3, R4, R5, R6, R8, R9, X, X1, X2, X3, L1 and n are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.Type: ApplicationFiled: May 16, 2018Publication date: April 22, 2021Inventors: Gareth Richards, Timothy M. Skerry, Joseph P.A. Harrity, Jean-Olivier Zirimwabagabo, Matthew J. Tozer, Karl Richard Gibson, Roderick Alan Porter, Paul Matthew Blaney, Paul Alan Glossop
-
Publication number: 20200369658Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: ApplicationFiled: August 11, 2020Publication date: November 26, 2020Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Patent number: 10774078Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: GrantFiled: June 21, 2019Date of Patent: September 15, 2020Assignee: MISSION THERAPEUTICS LTDInventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Patent number: 10683269Abstract: The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.Type: GrantFiled: March 17, 2017Date of Patent: June 16, 2020Assignee: MISSION THERAPEUTICS LIMITEDInventors: Karl Richard Gibson, Alison Jones, Mark Ian Kemp, Andrew Madin, Martin Lee Stockley, Gavin Alistair Whitlock, Michael D Woodrow, Keith Allan Menear
-
Publication number: 20200165259Abstract: The present invention relates to pyrrolopyrimidine compounds according to Formula I and their use in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases. In a particular aspect, the present compounds are ASK inhibitors, particularly ASK1 inhibitors. The present invention also provides methods for the production of a compound of the invention, pharmaceutical compositions comprising a compound of the invention, the use of the compounds in the prophylaxis and/or treatment of pain, inflammatory conditions, cardiovascular diseases, neurodegenerative diseases, neurological diseases, complications of type I diabetes, cancer and/or fibrotic diseases.Type: ApplicationFiled: July 12, 2018Publication date: May 28, 2020Inventors: David AMANTINI, Milan MESIC, Gordon SAXTY, Tanja POLJAK, Ines VUJASINOVIC, Dinko ZIHER, David WITTY, Karl Richard GIBSON
-
Patent number: 10640498Abstract: The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer.Type: GrantFiled: February 16, 2017Date of Patent: May 5, 2020Assignee: MISSION THERAPEUTICS LIMITEDInventors: Karl Richard Gibson, Alison Jones, Mark Ian Kemp, Andrew Madin, Martin Lee Stockley, Gavin Alistair Whitlock, Michael D. Woodrow
-
Publication number: 20190330202Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: ApplicationFiled: June 21, 2019Publication date: October 31, 2019Inventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew MADIN
-
Publication number: 20190055232Abstract: The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer.Type: ApplicationFiled: February 16, 2017Publication date: February 21, 2019Inventors: Karl Richard GIBSON, Alison JONES, Mark Ian KEMP, Andrew MADIN, Martin Lee STOCKLEY, Gavin Alistair WHITLOCK, Michael D. WOODROW
-
Publication number: 20190010122Abstract: The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.Type: ApplicationFiled: March 17, 2017Publication date: January 10, 2019Inventors: Karl Richard GIBSON, Alison JONES, Mark Ian KEMP, Andrew MADIN, Martin Lee STOCKLEY, Gavin Alistair WHITLOCK, Michael D WOODROW, Keith Allan MENEAR
-
Patent number: 10016420Abstract: The invention provides compounds of formula I, wherein: R1 represents a cyclic group selected from phenyl, heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl; wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, C1-6 alkyl optionally substituted with 1-3 halogen atoms, phenyl, C1-6 alkoxy optionally substituted with 1-3 halogen atoms, cyano, heteroaryl1a and heterocyclyl1a; and wherein each cyclic group is optionally fused to a benzene ring or a 5- or 6-membered heteroaromatic or heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N, O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl1 and heterocyclyl1a may additionally be substituted with ?O; X represents a bond or C1-6 alkylene (which may be straight or branched); R2 represents H or C1-6 alkyl; R3 represents H or C1-6 alkyl; Y represents a bond or C1-6 alkylene (which may be straightType: GrantFiled: January 19, 2016Date of Patent: July 10, 2018Assignee: INHIBITAXIN LIMITEDInventors: Karl Richard Gibson, Dafydd Rhys Owen
-
Patent number: 9926307Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: GrantFiled: September 22, 2015Date of Patent: March 27, 2018Assignee: MISSION THERAPEUTICS LTDInventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Publication number: 20170247365Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.Type: ApplicationFiled: September 22, 2015Publication date: August 31, 2017Applicants: MISSION THERAPEUTICS LTD, MISSION THERAPEUTICS LTDInventors: Alison Jones, Mark Ian Kemp, Martin Lee Stockley, Karl Richard Gibson, Gavin Alistair Whitlock, Andrew Madin
-
Publication number: 20160355528Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: ApplicationFiled: August 19, 2016Publication date: December 8, 2016Applicant: VIIV HEALTHCARE UK LIMITEDInventors: Andrew Simon BELL, Iain Brian GARDNER, Karl Richard GIBSON, David Cameron PRYDE, Florian Michel WAKENHUT
-
Publication number: 20160287584Abstract: The invention provides compounds of formula I, wherein: R1 represents a cyclic group selected from phenyl, heteroaryl1, heterocyclyl1 and C3-6 cycloalkyl; wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, C1-6 alkyl optionally substituted with 1-3 halogen atoms, phenyl, C1-6 alkoxy optionally substituted with 1-3 halogen atoms, cyano, heteroaryl1a and heterocyclyl1a; and wherein each cyclic group is optionally fused to a benzene ring or a 5- or 6-membered heteroaromatic or heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N, O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl1 and heterocyclyl1a may additionally be substituted with ?O; X represents a bond or C1-6 alkylene (which may be straight or branched); R2 represents H or C1-6 alkyl; R3 represents H or C1-6 alkyl; Y represents a bond or C1-6 alkylene (which may be straightType: ApplicationFiled: January 19, 2016Publication date: October 6, 2016Inventors: Karl Richard Gibson, Dafydd Rhys Owen
-
Patent number: 9447116Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: GrantFiled: July 2, 2014Date of Patent: September 20, 2016Assignee: ViiV Healthcare UK LimitedInventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Patent number: 9273011Abstract: The invention provides compounds of formula I, (I) wherein: R represents a cyclic group selected from phenyl, heteroaryl, heterocyclyl and C 3-6 cycloalkyl; 10 wherein each cyclic group is optionally substituted with from 1 to 3 substituents selected from halo, C -6 alkyl optionally substituted with 1-3 halogen atoms, phenyl, C -6 alkoxy optionally substituted with 1-3 halogen atoms, cyano, heteroaryl 1a and heterocyclyl 1a; and wherein each cyclic group is optionally fused to a benzene ring or a 5- or 16-membered heteroaromatic or heterocyclic ring each containing from 1 to 3 heteroatoms (selected from N, O and S); and when the group is substituted the substitution may occur anywhere on the optionally fused ring system as a whole; and wherein heterocyclyl and heterocyclyl 1a may additionally be substituted with ?O; 20 X represents a bond or C -6 alkylene (which may be straight or branched); R 2 represents H or C -6 alkyl; R 3 represents H or C -6 alkyl; Y represents a bond or C -6 alkylene (which may be straType: GrantFiled: October 26, 2012Date of Patent: March 1, 2016Assignee: Inhibitaxin LimitedInventors: Karl Richard Gibson, Dafydd Rhys Owen
-
Patent number: 9163021Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.Type: GrantFiled: September 26, 2013Date of Patent: October 20, 2015Assignee: Pfizer LimitedInventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
-
Publication number: 20150246912Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.Type: ApplicationFiled: September 26, 2013Publication date: September 3, 2015Applicant: Pfizer LimitedInventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple